1.
Bioorg Med Chem Lett
; 17(8): 2134-8, 2007 Apr 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-17303421
RESUMEN
A novel series of quinolinyl-methylene-thiazolinones has been identified as potent and selective cyclin-dependent kinase 1 (CDK1) inhibitors. Their synthesis and structure activity relationships (SAR) are described. Representative compounds from this class reversibly inhibit CDK1 activity in vitro, and block cell cycle progression in human tumor cell lines, suggesting a potential use as antitumor agents.